On the trail of missing genes and cancer clues
LJI scientists connect TET loss of function to missing genes in embryonic stem cells
Investigating cancer drug toxicity leads to a critical discovery
LA JOLLA—It’s not often that a failed clinical trial leads to a scientific breakthrough. When patients in the UK started
Strange DNA structures may drive cancer development
LJI researchers shed light on the role of TET enzymes in genomic stability and cancers
Six LJI scientists named “Highly Cited Researchers”
The international recognition reflects how LJI research is valued by scientific peers
Immune cells can detect cancer
Now we can see what they see — and help
Preparing T cells for the long haul
New LJI research could keep cancer-fighting T cells from burning out before the job is done
Many cancer patients may need a sequential one-two punch of immunotherapies
Treating patients with anti-CTLA4 therapies prior to anti-PD1 treatment may be a promising strategy
Timothy Baffi receives ACS award to study acute myeloid leukemia
New support from the American Cancer Society fuels research into the primary mutations behind many cancer types
LJI launches new global cancer immunology resource
National Cancer Institute support brings cancer researchers together to share key findings
Learning from men. Learning from women.
Men and women have different immune systems. With a better understanding of sex-specific immune differences, scientists can more effectively fight infections, cancers, heart disease, and even pregnancy complications.
Amnon Altman: Leading immunologist and educator retires
Dr. Altman’s research into T cell activation opened the door to new therapies for inflammation, autoimmune diseases, cancers, and more.
A clue to how some fast-growing tumors hide in plain sight
New LJI research could guide the development of more effective cancer immunotherapies